Development of gene replacement therapy for Sanfilippo Syndrome Type C

C 型桑菲利波综合征的基因替代疗法的开发

基本信息

  • 批准号:
    10541309
  • 负责人:
  • 金额:
    $ 149.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-19 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Lysosomal storage diseases (LSD) are rare inherited metabolic disorders caused by defects in the cellular catabolic system. Mucopolysaccharidosis Type IIIC (MPS IIIC or Sanfilippo disease type C) is one such LSD that is caused by deficiency of the enzyme heparan sulfate acetyl CoA: -glucosaminide N-acetyltransferase, (HGSNAT) essential for degradation of heparan sulfate, a repeating carbohydrate generally found attached to proteoglycans. This disease causes accumulation of heparan sulfate resulting in a progressive and severe neurological deterioration early in life with little somatic features. The symptoms in patients with MPS IIIC may present at an average age of 3.5 years of age with psychomotor developmental delays and behavioral problems. Before the age of 15 years verbal communication is often lost in patients with MPS IIIC. Most lose the ability to walk between the 20 and 30 years of age. The condition is fatal by an average age of 34 years (range, 25-48). Enzyme replacement therapies are not an option since the protein is localized and bound to lysosomal membrane. There are currently no treatments available for treatment of MPS IIIC. Individuals affected by MPS IIIC are managed with supportive care, consultation with medical professionals from multiple disciplines, physical therapy, and pharmacological interventions to alleviate symptoms. Gene therapy represents a reasonable and promising approach to provide a meaningful and long-term therapeutic benefit for this population in the near future. The goal of this SBIR project is to complete tissue level assessments in the disease model, scale up manufacturing and establish safety on a GLP regulated study in rats. These activities will help build a robust briefing package for IND-filing for our gene therapy product, JLK-247. The progress will help us navigate the “valley of death” by establishing milestones and making go/no-go decisions. The safe therapeutic dose-range established will help us extrapolate and translate therapeutic doses to clinical phase I trials. This proposal leverages the scientific expertise in gene therapy preclinical development and regulatory experience of Srikanth Singamsetty, PhD (Phoenix Nest, Inc.) for the product development. Jill Wood, BS (Phoenix Nest, Inc.), will manage the project finances and personnel responsible. Professor Steven Gray, PhD (The University of Texas Southwestern Medical Center, Dallas, TX) is our gene therapy subject matter expert. Successful completion of this project will help with initiating clinical trial dosing, a first step towards a long-term therapy for MPSIIC, a dreadful and fatal pediatric disease.
项目摘要/摘要 溶酶体贮积病(LSD)是一种罕见的遗传性代谢紊乱, 分解代谢系统粘多糖样变性IIIC型(MPS IIIC或Sanfilippo病C型)就是这样一种LSD 其由硫酸乙酰肝素乙酰辅酶A:β-氨基葡萄糖苷N-乙酰转移酶的缺乏引起, (HGSNAT)对于硫酸乙酰肝素的降解是必需的,硫酸乙酰肝素是一种重复的碳水化合物, 蛋白聚糖这种疾病引起硫酸乙酰肝素的积累,导致进行性和严重的 生命早期的神经系统退化,几乎没有躯体特征。MPS IIIC患者的症状可能 平均年龄为3.5岁,患有精神发育迟缓和行为问题。 在15岁之前,MPS IIIC患者经常失去语言交流。大多数人失去了 在20到30岁之间走路。这种情况是致命的平均年龄为34岁(范围,25-48)。 酶替代疗法不是一种选择,因为蛋白质是本地化的,并结合到溶酶体 膜的目前尚无治疗MPS IIIC的方法。受影响的个人 MPS IIIC通过支持性治疗进行管理,咨询多个学科的医学专业人员, 物理治疗和药物干预以缓解症状。基因治疗代表了 为该人群提供有意义的长期治疗获益的合理且有前景的方法 在近期 该SBIR项目的目标是在疾病模型中完成组织水平评估, 在大鼠中进行GLP监管研究,并确定其安全性。这些活动将有助于建立一个强大的 我们基因治疗产品JLK-247的IND申报简报包。这些进展将帮助我们 通过建立里程碑和做出去/不去的决定来实现“死亡之谷”。安全治疗剂量范围 这将帮助我们推断并将治疗剂量转化为临床I期试验。 该提案利用了基因治疗临床前开发和监管方面的科学专业知识, Srikanth Singamsetty博士(Phoenix Nest,Inc.)的经验为产品开发。Jill Wood,理学学士 (Phoenix Nest,Inc.),将负责管理项目的财务和人员。Steven Gray教授,博士 (The德克萨斯大学西南医学中心,达拉斯,TX)是我们的基因治疗主题专家。 该项目的成功完成将有助于启动临床试验剂量,这是迈向长期的第一步。 MPSIIC是一种可怕而致命的儿科疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Srikanth Singamsetty其他文献

Srikanth Singamsetty的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Srikanth Singamsetty', 18)}}的其他基金

Development of Gene Replacement Therapy for Sanfilippo Syndrome Type C
C 型 Sanfilippo 综合征基因替代疗法的开发
  • 批准号:
    10706562
  • 财政年份:
    2022
  • 资助金额:
    $ 149.56万
  • 项目类别:
Evaluation of clinical outcome assessment (COA) and potential biomarkers to Facilitate Interventionaltrial for Mucopolysaccharidosis IIID Patients
临床结果评估 (COA) 和潜在生物标志物的评估,以促进粘多糖贮积症 IIID 患者的介入试验
  • 批准号:
    10325321
  • 财政年份:
    2021
  • 资助金额:
    $ 149.56万
  • 项目类别:
Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients
临床结果评估 (COA) 和潜在生物标志物的评估,以促进粘多糖贮积症 IIID 患者的介入试验
  • 批准号:
    10599310
  • 财政年份:
    2021
  • 资助金额:
    $ 149.56万
  • 项目类别:

相似海外基金

The Language Environment in Fostering 5-Year-Old Children's Voluntary Involvements
培养5岁儿童自愿参与的语言环境
  • 批准号:
    22K13681
  • 财政年份:
    2022
  • 资助金额:
    $ 149.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Study of Reading Picture Books In 5-Year-Old Class and the Support Process of the Teachers
五岁班绘本阅读研究及教师支持过程
  • 批准号:
    19K14156
  • 财政年份:
    2019
  • 资助金额:
    $ 149.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Improving motor skills in 3-5 year old children with Autism Spectrum Disorder: Effects on the family unit.
提高患有自闭症谱系障碍的 3-5 岁儿童的运动技能:对家庭单位的影响。
  • 批准号:
    386469
  • 财政年份:
    2017
  • 资助金额:
    $ 149.56万
  • 项目类别:
    Studentship Programs
Epidemiological study and Creating new diagnostic methods for Neurodevelopmental disorders in 5-year-old children
5岁儿童神经发育障碍流行病学研究及诊断新方法
  • 批准号:
    16K10239
  • 财政年份:
    2016
  • 资助金额:
    $ 149.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Differences in motor milestone attainment in 4- and 5-year old children at risk for Developmental Coordination Disorder
有发育协调障碍风险的 4 岁和 5 岁儿童在运动里程碑方面的差异
  • 批准号:
    324425
  • 财政年份:
    2015
  • 资助金额:
    $ 149.56万
  • 项目类别:
Prevalence and social determinants of developmental outcomes among 5-year-old children with health disorders: A Pan-Canadian study
5 岁儿童健康障碍的患病率和发育结果的社会决定因素:一项泛加拿大研究
  • 批准号:
    322111
  • 财政年份:
    2015
  • 资助金额:
    $ 149.56万
  • 项目类别:
    Operating Grants
Fornative Expressive Behavior in Children's (4 years old and 5 year-old) Artistic Play Activities
儿童(4岁和5岁)艺术游戏活动中的本能表达行为
  • 批准号:
    26780506
  • 财政年份:
    2014
  • 资助金额:
    $ 149.56万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The development which is a shift support program to a 1st grader of elementary school from 5-year old children who prevents "a 1st grade of elementary school, problem"
作为防止"小学一年级、问题"的5岁儿童到小学一年级学生的轮班支援计划的展开
  • 批准号:
    25381292
  • 财政年份:
    2013
  • 资助金额:
    $ 149.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of behavioural measures of sentence comprehension in 2 to 5 year old children
2至5岁儿童句子理解行为测量的发展
  • 批准号:
    449402-2013
  • 财政年份:
    2013
  • 资助金额:
    $ 149.56万
  • 项目类别:
    University Undergraduate Student Research Awards
Technology development and neuroimaging for 5 year old children with HIV infectio
5 岁 HIV 感染儿童的技术开发和神经影像学
  • 批准号:
    8333355
  • 财政年份:
    2011
  • 资助金额:
    $ 149.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了